Sébastien Depienne
Research Subjects
Research Interests
Sébastien Depienne has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aurélien Dupont
UAR Biosit
1 shared publication - David Deniaud
Nantes Université
1 shared publication - Denis Loquet
Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation
1 shared publication - Dimitri Alvarez-Dorta
Capacités, SAS, Nantes 44200, France
1 shared publication - Karine Pavageau
Translational Research in Gene Therapy
1 shared publication - Maia Marchand
Nantes Université, TaRGeT, Translational Research for Gene Therapies, CHU Nantes, INSERM, UMR 1089, Nantes 44000, France
1 shared publication
Latest Publications
- Open Access
- 29 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Bioorthogonal chemical engineering of rAAV capsid: Advancing gene therapy targeting using proteins
We report the chemical conjugation of recombinant Adeno Associated Virus (rAAV) capsid with various functionalities, including proteins, using a bioorthogonal strategy. rAAVs were azido-coated or DBCO-coated by chemically modifying lysine or tyrosine residues. Lysine residues were modified using a phenyl isothiocyanate anchor, and tyrosine residues using either an aryldiazonium salt or a N-methyl luminol derivative. We demonstrate anchor- dependent labelling levels, as observed with biochemical assays and mass spectrometry. Strain-promoted azide-alkyne cycloaddition (SPAAC) was then implemented and evaluated on the rAAV to append functionalities such as fluorescein, biotin and carbohydrates to the azido- coated capsids. We confirmed the efficiency of the bioorthogonal reaction and observed a stronger reactivity with dibenzylcyclooctyne (DBCO) compared to bicyclononyne (BCN). The optimized SPAAC reaction was finally used to label the viral vectors with two relevant nanobodies targeting specific immune cell receptors (CD62L and CD45). In vitro transduction assays conducted with one rAAV-nanobody conjugate demonstrated the promising targeting properties of these chemically modified vectors. Thus, we anticipate that this strategy will positively impact the field of rAAV capsid engineering and contribute in tissue-specific targeting for the optimisation of gene therapy treatments.
- 29 July 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBioorthogonal chemical engineering of rAAV capsid: Advancing gene therapy targeting using proteins
We report the chemical conjugation of recombinant Adeno Associated Virus (rAAV) capsid with various functionalities, including proteins, using a bioorthogonal strategy. rAAVs were azido-coated or DBCO-coated by chemically modifying lysine or tyrosine residues. Lysine residues were modified using a phenyl isothiocyanate anchor, and tyrosine residues using either an aryldiazonium salt or a N-methyl luminol derivative. We demonstrate anchor- dependent labelling levels, as observed with biochemical assays and mass spectrometry. Strain-promoted azide-alkyne cycloaddition (SPAAC) was then implemented and evaluated on the rAAV to append functionalities such as fluorescein, biotin and carbohydrates to the azido- coated capsids. We confirmed the efficiency of the bioorthogonal reaction and observed a stronger reactivity with dibenzylcyclooctyne (DBCO) compared to bicyclononyne (BCN). The optimized SPAAC reaction was finally used to label the viral vectors with two relevant nanobodies targeting specific immune cell receptors (CD62L and CD45). In vitro transduction assays conducted with one rAAV-nanobody conjugate demonstrated the promising targeting properties of these chemically modified vectors. Thus, we anticipate that this strategy will positively impact the field of rAAV capsid engineering and contribute in tissue-specific targeting for the optimisation of gene therapy treatments.